GLOBE LIFE INC. ANNOUNCES THIRD QUARTER 2022 EARNINGS RELEASE AND CONFERENCE CALL
MCKINNEY, Texas, Oct. 24, 2022 /PRNewswire/ -- Globe Life Inc. (NYSE: GL) will release Third Quarter 2022 earnings after the market closes on Wednesday, October 26, 2022. At that time a copy of the Company's Q3 - 2022 earnings press release and any other financial and statistical information about the quarter will be available on the Company's website at https://investors.globelifeinsurance.com/ under Financial Reports and Other Financial Information. In conjunction with the Third Quarter 2022 Earnings Release of Globe Life Inc. you are invited to listen to a conference call that will be broadcast live over the Internet on Thursday, October 27, 2022 at 11:00 am Eastern (10:00 am Central).
Third Quarter Conference Call Thursday, October 27, 2022 11:00 a.m. (Eastern)
Globe Life Inc. is a holding company specializing in life and supplemental health insurance for "middle income" Americans marketed through multiple distribution channels including direct to consumer, and exclusive and independent agencies.
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
